Thera-SAbDab

TIMCEVIBART

> Structural Summary

Therapeutic	Timcevibart
Target	SARS-CoV-2 Spike RBD
Heavy Chain	QVQLVESGGGLVQPGGSLRLSCAASGLTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCARDVADAFDIWGQGTMVTVSS
Light Chain	DIVMTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCQQLNSYPPFTFGPGTKVDIK
100% seqID Fv Structure	7b3o [Fvs: HL]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	7b3o [Fvs: HL]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder2
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (Aug '24)	TBC
Estimated Status (Aug '24)	Active
Recorded Developmental Technology
INN Year Proposed	2023
INN Year Recommended	None
Companies Involved	TBC
Conditions Approved	TBC
Conditions Active	TBC
Conditions Discontinued	TBC
Notes	8elo:HL is 94.6% identical

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy